Drug
OGX-011 clinical trials
Also written OGX-011, custirsen sodium and TV-1011.
- studies test it
- 10
- open now
- 0
- in phase 3
- 4
- first study started
- 2004
How studies write it
Studies that test it under each name
Other names
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2010 | 2 |
| 2012 | 3 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 4
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 2
Achieve Life Sciences (8) · NCIC Clinical Trials Group (1) · University of British Columbia (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses OGX-011 is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung CancerCompletedPhase 3Achieve Life SciencesNCT01630733Written as Custirsen
- Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone TherapyCompletedPhase 2NCIC Clinical Trials GroupNCT00258388Written as custirsen sodium
- Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate CancerCompletedPhase 2University of British ColumbiaNCT00138918Written as OGX-011
- Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate CancerCompletedPhase 3Achieve Life SciencesNCT01188187Written as Custirsen
- Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate CancerCompletedPhase 3Achieve Life SciencesNCT01578655Written as custirsen sodium
- A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)TerminatedPhase 3Achieve Life SciencesNCT01083615Written as custirsen sodium
- Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac RepolarizationCompletedPhase 1Achieve Life SciencesNCT01874561Written as Custirsen
- A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment RegimenCompletedPhase 1Achieve Life SciencesNCT01497470Written as Custirsen, paclitaxel and carboplatin
- Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPCCompletedPhase 2Achieve Life SciencesNCT00327340Written as custirsen (OGX-011)/mitoxantrone
- A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1/2Achieve Life SciencesNCT00138658Written as custirsen sodium
Codes
What other systems call OGX-011 · ClinicalTrials.gg INT004812
Also registered as custirsen (UNII L26E95NLRK) and custirsen sodium (UNII ILE26V76EB).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.